未登录

A

Ana Katrina Mapanao

psi center for life sciences

H指数:17

被引数:689

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Tolerability of [161Tb]Tb-SibuDAB in comparison to other PSMA-targeting radioligands in the preclinical setting

[161Tb]Tb-SibuDAB与其他PSMA靶向放射性配体的耐受性比较：在预临床研究中的评估

European Journal of Nuclear Medicine and Molecular Imaging

IF7.6

2026-08-130

OA

Preclinical characterization of FAP-targeting radioconjugates: assessing biophysical and pharmacokinetic equivalence of lutetium-177 and terbium-161

FAP靶向放射性偶联物的临床前表征：评估镥-177和铽-161的生物物理和药代动力学等效性

EJNMMI Research

IF3

2026-07-290

OA

Biodistribution and dosimetry of [177Lu]Lu-SibuDAB in patients with metastatic castration-resistant prostate cancer

[177Lu]Lu-SibuDAB在转移性去势抵抗性前列腺癌患者中的生物分布和剂量学研究

EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING

IF7.6

2025-02-030

OA

Preclinical investigation of [149Tb]Tb-DOTATATE and [149Tb]Tb-DOTA-LM3 for tumor-targeted alpha therapy

European Journal of Nuclear Medicine and Molecular Imaging

IF7.6

2025-01-020

PRE

Preclinical comparison of (radio)lanthanides using mass spectrometry and nuclear imaging techniques: biodistribution of lanthanide-based tumor-targeting agents and lanthanides in ionic form

European Journal of Nuclear Medicine and Molecular Imaging

IF7.6

2024-12-160

OAAI

Comparison of the tolerability of 161Tb- and 177Lu-labeled somatostatin analogues in the preclinical setting

European Journal of Nuclear Medicine and Molecular Imaging

IF7.6

2024-07-242

OAAI

Tumor growth-arrest effect of tetrahydroquinazoline-derivative human topoisomerase II-alpha inhibitor in HPV-negative head and neck squamous cell carcinoma

SCIENTIFIC REPORTS

IF3.9

2024-04-211

OAAI

A tool for nuclear imaging of the SARS-CoV-2 entry receptor: molecular model and preclinical development of ACE2-selective radiopeptides

EJNMMI RESEARCH

IF3

2023-04-197

OAAI

Hyperthermia Reduces Irradiation-Induced Tumor Repopulation in an In Vivo Pancreatic Carcinoma Model

在体内胰腺癌模型中，高温可减少辐射诱导的肿瘤再增殖

ADVANCED BIOLOGY

IF2.6

2023-03-026

OAAI

Hybrid nano-architectures loaded with metal complexes for the co-chemotherapy of head and neck carcinomas

JOURNAL OF MATERIALS CHEMISTRY B

IF5.7

2023-01-0111

OA

The Fate of Intranasally Instilled Silver Nanoarchitectures

IF9.1

2022-06-3013

OAAI

Experimental Evaluation of Radiation Response and Thermal Properties of NPs-Loaded Tissues-Mimicking Phantoms

IF4.3

2022-03-1313

OAAI

Pro-apoptotic and size-reducing effects of protein corona-modulating nano-architectures enclosing platinum prodrug in in vivo oral carcinoma

BIOMATERIALS SCIENCE

IF5.7

2022-01-0116

OA

Tumor grafted - chick chorioallantoic membrane as an alternative model for biological cancer research and conventional/nanomaterial-based theranostics evaluation

EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY

IF3.4

2021-02-1039

OAAI

Ruthenium arene complexes in the treatment of 3D models of head and neck squamous cell carcinomas

EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY

IF5.9

2021-02-0117

PREAI

Combined chemo-photothermal treatment of three-dimensional head and neck squamous cell carcinomas by gold nano-architectures

JOURNAL OF COLLOID AND INTERFACE SCIENCE

IF9.7

2021-01-0142

PREAI

Production of 3D Tumor Models of Head and Neck Squamous Cell Carcinomas for Nanotheranostics Assessment

ACS BIOMATERIALS SCIENCE & ENGINEERING

IF5.5

2020-07-0123

OAAI

Three-dimensional tumor models: Promoting breakthroughs in nanotheranostics translational research

APPLIED MATERIALS TODAY

IF6.9

2020-06-0139

PREAI

Photothermal effect by NIR-responsive excretable ultrasmall-in-nano architectures

MATERIALS HORIZONS

IF10.7

2019-01-0148

OAAI

Endogenously Triggerable Ultrasmall-in-Nano Architectures: Targeting Assessment on 3D Pancreatic Carcinoma Spheroids

IF4.3

2018-09-2428

OAAI